Pergonal market forecast points to stronger fertility treatment demand

The Business Research Company says the Pergonal market is set to grow through 2035 as infertility rises, IVF use expands and healthcare spending climbs. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Pergonal is tied to fertility care, so market growth tracks broader demand for infertility treatment and assisted reproductive technologies. - The market outlook reflects more women seeking fertility therapies, wider access to gynecology services and stronger investment in reproductive medicine. - Rising use of hormone-based treatments and IVF could expand demand for ovulation-stimulating drugs like Pergonal.

What happened: - The Business Research Company published the Pergonal Market Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report says the Pergonal market is gaining momentum as infertility rates rise and fertility treatment becomes more accessible worldwide. - A free sample of the report is available here. - The full report is available here.

The details: - Pergonal is a biologic medication made from human menopausal gonadotropin, or hMG, which includes luteinizing hormone and follicle-stimulating hormone. - The drug is used in fertility therapy to stimulate ovulation in women with ovulatory disorders. - Pergonal is derived from the urine of postmenopausal women. - The report links past market growth to more infertility cases, greater awareness of fertility therapies, broader clinical gynecology access, hormone-based infertility drugs and older maternal age. - The report expects future growth from higher demand for assisted reproductive technologies, more investment in fertility care facilities, personalized hormone treatment, wider access in emerging markets and more clinical research in reproductive endocrinology. - Major market trends include broader use of hormonal fertility treatments, more uptake of assisted reproductive procedures, increased use of urine-derived gonadotropins, more specialized fertility clinics and customized ovulation induction protocols. - The report identifies infertility as a major driver because delayed childbearing, lifestyle factors, environmental toxins, PCOS and endometriosis are increasing demand for treatment. - The World Health Organization said in April 2023 that about 17.5% of adults globally, or 1 in 6 people, experience infertility. - IVF adoption is also lifting demand because Pergonal helps stimulate the ovaries to produce multiple mature eggs. - The UK’s Human Fertilisation & Embryology Authority said in June 2025 that more than 52,400 patients underwent more than 77,500 IVF cycles at licensed UK fertility clinics in 2023. - Egg freezing cycles in the UK rose from 4,700 in 2022 to 6,900 in 2023, equal to 7% of all cycles. - Expanding healthcare spending is supporting access to advanced fertility treatment and assisted reproductive technologies. - The UK’s Office for National Statistics said in May 2023 that healthcare expenditure rose 5.6% between 2022 and 2023, compared with 0.9% growth in 2022. - UK healthcare spending reached about $317.63 billion, or £292 billion, in 2023. - North America was the largest Pergonal market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated technology and trend analysis.

Between the lines: - The report positions Pergonal as a proxy for wider fertility-treatment demand, not just a standalone drug category. - The strongest growth signals come from structural shifts: later parenthood, higher infertility rates and greater use of assisted reproduction. - Regional growth is likely to be uneven, with mature markets leading today and emerging markets expected to drive faster expansion later.

What's next: - The market will likely track IVF volume, fertility-clinic expansion and adoption of personalized hormone treatment over the forecast period. - More healthcare investment in emerging economies could widen access to fertility therapies and support regional growth outside North America. - The Business Research Company is promoting expanded strategic intelligence tools in its 2026 reports, which may shape how buyers evaluate future market opportunities.

The bottom line: - Pergonal’s growth story is really a fertility-market story: more infertility, more IVF and more spending on reproductive care are pushing demand higher.